ArticleTherapeutic advances in neurological disorders2026
Brain age gap in multiple sclerosis: associated with disability but independent of serum biomarkers.
Article in Therapeutic advances in neurological disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
End of Dose Phenomena in Subcutaneous Natalizumab Treated MS Patients
Strategies for Adaptive Follow-up and Evaluation - Guiding Use of Indicators for De-Escalation in Multiple Sclerosis
Measuring Silent Disease Progression in Multiple Sclerosis With a Multimodal Approach
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple sclerosis (MS) is influenced by age-related brain alterations and affects cellular aging mechanisms. Machine-learning models can estimate brain-predicted age from magnetic resonance imaging (MRI) to quantify these aging-related changes. Objectives: This study examines whether the difference between predicted and chronological age (BrainAGE) relates to clinical disability and biomarkers of neuro-axonal injury in MS. Design: This study analyzed brain-predicted age from structural 3D T1-weighted MRI in 82 patients with relapsing MS enrolled in three prospective clinical trials and 30 healthy controls. Methods: BrainAGE, calculated as MRI-predicted minus chronological age, was correlated with the Expanded Disability Status Scale (EDSS), MS Functional Composite subtests, and serum neurofilament light chain and glial fibrillary acidic protein. Results: The mean chronological age of patients and healthy controls included in this study was 39.2 and 40.9 years, respectively. Patients with MS ( Conclusion: Our findings suggest that BrainAGE and serum biomarkers capture complementary aspects of MS pathology, supporting a multimodal approach to assess disease progression. Trial registration: ClinicalTrials.gov ID: SATURATE: NCT05701423, 360PMS: NCT06501950, SAFEGUIDE-MS: NCT06461481.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.